10:00 am Chair’s Opening Remarks

Defining the Criteria of What Makes a Good Target

10:00 am Looking into Novel ADC Targets with Unique Properties


• “Casting a wide net” – target scouting in silico
• Assess biological considerations in target selection
• Stepwise in vitro/in vivo proof of concept – and beyond

10:30 am Every Antigen is a Target – If we Invent the Right Drug!

  • Bill Mallet Staff Scientist, Target Validation Bolt Bio


• We have many good targets but no perfect ones – review some key steps to building a strong target validation package
• Every target has a liability – understand what we can tolerate, what we should avoid, and when our assumptions should be put aside
• Evaluate case studies including target validation for cytotoxic ADCs and immunotherapies

11:00 am Virtual Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC Targets field and establish meaningful business relationships to pursue for the rest of the conference.

Exploring the Target-Payload Selection

12:00 pm Target Expression & Warhead: The Driving Forces of ADC Activity


• How much target expression is needed for ADC activity?
• Do we know the correlation between level of expression and payload type?
• Could testing ADC activity in 3D tumor organoid systems give better clinical translation in terms of ADC activity as related to target expression and payload?

12:30 pm Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induces Potent Anti- Tumor Immunity

  • Tracy Kuo Senior Director - Biology & Translational Science, Tallac Therapeutics


• Identify how activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides promotes innate inflammatory responses and induction of adaptive immunity
• Review our novel Toll-Like Receptor Agonist Antibody Conjugate (TRAAC) platform developed to deliver a potent TLR9 (T-CpG agonist for targeted immune activation via systemic administration
• Evaluate various TRAAC approaches targeting either immune cell receptor or tumor specific antigens in preclinical settings

1:00 pm Lunch & Networking

Exploring the Target-Payload Selection

2:00 pm Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug

Looking at Novel Targets & The Future of Targets for ADCs

2:30 pm Targeting EGFR Through ADCs


• Delving into the history of this target
• Understanding the lessons learned from working on this target
• Looking into future perspectives

3:00 pm Targeting Leukaemias with Anti-CD7 Antibody & ADC


• Assessing how T cell leukaemias, some acute myeloid and relapsed, refractory leukaemias express CD7 antigen on their surface
• Discussing how a novel antibody-drug conjugate kills CD7 expressing leukaemias suggesting a target and linker combination for treatment of CD7-expressing cancers
• Understanding how CD7 bound by antibody is rapidly processed into cells and internalization could also be exploited to introduce other druglike molecules into cancer cells in vivo

3:30 pm Chair’s Closing Remarks